Marshall Wace, LLP Atara Biotherapeutics, Inc. Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.44 - $1.22 $110,113 - $305,314	-250,258 Reduced 85.56%	42,242 $29,000
Q4 2023 Feb 14, 2024	BUY	$0.23 - $1.74 $67,275 - $508,950	292,500 New	292,500 $149,000
Q2 2023 Aug 14, 2023	BUY	$1.5 - $3.04 $93,270 - $189,027	62,180 New	62,180 $100,000
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $218,327 - $668,770	76,606 New	76,606 $290,000
Q2 2021 Aug 13, 2021	SELL	$12.89 - $16.58 $983,171 - $1.26 Million	-76,274 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$14.0 - $20.72 $7.79 Million - $11.5 Million	-556,469 Reduced 87.95%	76,274 $1.1 Million
Q4 2020 Feb 16, 2021	BUY	$12.67 - $26.23 $4.54 Million - $9.39 Million	358,073 Added 130.36%	632,743 $12.4 Million
Q3 2020 Nov 16, 2020	SELL	$11.92 - $15.87 $5.93 Million - $7.89 Million	-497,296 Reduced 64.42%	274,670 $3.56 Million
Q2 2020 Aug 13, 2020	BUY	$7.53 - $14.93 $5.81 Million - $11.5 Million	771,966 New	771,966 $11.2 Million
Q2 2019 Aug 14, 2019	SELL	$19.05 - $41.04 $136,283 - $293,600	-7,154 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$28.4 - $41.74 $203,173 - $298,607	7,154 New	7,154 $284,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.